Last edition
News about "triple-negative breast cancer "
CStone's CS2009 Secures U.S. FDA IND Clearance for Phase II Trial in Advanced Solid Tumours
CStone Pharmaceuticals has received U.S. FDA IND clearance to begin a Phase II trial of its trispecific antibody CS2009 for advanced solid tumours, advancing its global immunotherapy development programme.
Triple-Negative Breast Cancer | 16/02/2026 | By News Bureau
Daiichi Sankyo Submits sNDA in Japan for Datroway in First-Line Metastatic TNBC
Daiichi Sankyo files supplemental application in Japan for Datroway as a first-line treatment for metastatic triple negative breast cancer based on phase III trial data.
Triple Negative Breast Cancer | 13/02/2026 | By News Bureau
The FDA has granted Priority Review to Datroway for first-line treatment of metastatic triple-negative breast cancer patients ineligible for immunotherapy, with a regulatory decision expected in Q2 2026.
Triple-negative Breast Cancer | 04/02/2026 | By News Bureau
Common Cholesterol Drug Shows Promise Against Drug-Resistant Breast Cancer
Korea University researchers show the cholesterol drug inhibits Mcl-1, suppresses metastasis, and restores chemotherapy sensitivity in preclinical models of aggressive TNBC.
Triple-negative Breast Cancer | 08/01/2026 | By News Bureau | 151
Mabwell Gets NMPA Approval for Clinical Trial of Nectin-4 Targeting ADC in TNBC
Mabwell has announced that its novel Nectin-4 targeting ADC has been approved by the NMPA to enter Phase II clinical trial as monotherapy or in combination with a PD-1 inhibitor for the treatment of triple-negative breast cancer (TNBC).
Triple-negative Breast Cancer | 16/07/2024 | By Aishwarya | 237
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy